Chao Yan

Dr. Chao Yan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2023 in Redox Biology
Verified
Journal Article
Open access
LYLizhong Yao
Lizhong Yao
JHJunyi Hou
Junyi Hou
XWXiongyan Wu
Xiongyan Wu
YLYifan Lu
Yifan Lu
ZJZhijian Jin
Zhijian Jin
LSLiping Su
Liping Su
As the predominant immunosuppressive component within the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) inhibit Natural Killer cell (NK cell) activity to promote tumor progression and immune escape; however, the mechanisms of cross-talk between CAFs and NK cells in gastric cancer (GC) remain poorly understood. In this study, we demonstrate that NK cell levels are inversely correlated with CAFs abundance in human GC. CAFs impair the anti-tumor capacity of NK cells by inducing ferroptosis, a cell death process characterized by the accumulation of iron-dependent lipid peroxides. CAFs induce ferroptosis in NK cells by promoting iron overload; conversely, decreased intracellular iron levels protect NK cells against CAF-induced ferroptosis. Mechanistically, CAFs increase the labile iron pool within NK cells via iron export into the TME, which is mediated by the upregulated expression of iron regulatory genes ferroportin1 and hephaestin in CAFs. Moreover, CAF-derived follistatin like protein 1(FSTL1) upregulates NCOA4 expression in NK cells via the DIP2A-P38 pathway, and NCOA4-mediated ferritinophagy is required for CAF-induced NK cell ferroptosis. In a human patient-derived organoid model, functional targeting of CAFs using a combination of deferoxamine and FSTL1-neutralizing antibody significantly alleviate CAF-induced NK cell ferroptosis and boost the cytotoxicity of NK cells against GC. This study demonstrates a novel mechanism of suppression of NK cell activity by CAFs in the TME and presents a potential therapeutic approach to augment the immune response against GC mediated by NK cells.

14 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YCYong Chen
Yong Chen
WXWenqi Xi
Wenqi Xi
WYWeiwu Yao
Weiwu Yao
LWLingyun Wang
Lingyun Wang
ZXZhihan Xu
Zhihan Xu
HZHuan Zhang
Huan Zhang
Objective: To develop and validate a dual-energy computed tomography (DECT) derived radiomics model to predict peritoneal metastasis (PM) in patients with gastric cancer (GC). Methods: This retrospective study recruited 239 GC (non-PM = 174, PM = 65) patients with histopathological confirmation for peritoneal status from January 2015 to December 2019. All patients were randomly divided into a training cohort (n = 160) and a testing cohort (n = 79). Standardized iodine-uptake (IU) images and 120-kV-equivalent mixed images (simulating conventional CT images) from portal-venous and delayed phases were used for analysis. Two regions of interest (ROIs) including the peritoneal area and the primary tumor were independently delineated. Subsequently, 1691 and 1226 radiomics features were extracted from the peritoneal area and the primary tumor from IU and mixed images on each phase. Boruta and Spearman correlation analysis were used for feature selection. Three radiomics models were established, including the R_IU model for IU images, the R_MIX model for mixed images and the combined radiomics model (the R_comb model). Random forest was used to tune the optimal radiomics model. The performance of the clinical model and human experts to assess PM was also recorded. Results: Fourteen and three radiomics features with low redundancy and high importance were extracted from the IU and mixed images, respectively. The R_IU model showed significantly better performance to predict PM than the R_MIX model in the training cohort (AUC, 0.981 vs. 0.917, p = 0.034). No improvement was observed in the R_comb model (AUC = 0.967). The R_IU model was the optimal radiomics model which showed no overfitting in the testing cohort (AUC = 0.967, p = 0.528). The R_IU model demonstrated significantly higher predictive value on peritoneal status than the clinical model and human experts in the testing cohort (AUC, 0.785, p = 0.005; AUC, 0.732, p <0.001, respectively). Conclusion: DECT derived radiomics could serve as a non-invasive and easy-to-use biomarker to preoperatively predict PM for GC, providing opportunity for those patients to tailor appropriate treatment.

4 February 2022 in Future Oncology
Verified
Journal Article
Open access
SLSheng Lu
Sheng Lu
ZYZhong-Yin Yang
Zhong-Yin Yang
CYChao Yan
Chao Yan
WLWen-Tao Liu
Wen-Tao Liu
ZNZhen-Tian Ni
Zhen-Tian Ni
ZZZheng-Gang Zhu
Zheng-Gang Zhu
Although recent advances in systemic chemotherapy have improved the clinical outcomes of gastric cancer patients with peritoneal metastasis, the peritoneum still represents a common site of treatme... Plain language summary Recent advances in technology have improved the outcomes of stomach cancer patients. However, there are still many patients who die of cancer that has spread from another par...

14 July 2025 in Gastric Cancer
Verified
Journal Article
Open access
PDF file
ZZZhenggang Zhu
Zhenggang Zhu
JKJoji Kitayama
Joji Kitayama
HKHyung-Ho Kim
Hyung-Ho Kim
Jimmy Bok-Yan SoJimmy Bok-Yan So
Jimmy Bok-Yan So
HCHui Cao
Hui Cao
AGAsian Gastric Cancer NIPS Treatment Collaborative Group
Asian Gastric Cancer NIPS Treatment Collaborative Group
Peritoneal metastasis (PM) is a major challenge in advanced gastric cancer (GC) with poor prognosis. Normothermic intraperitoneal and systemic treatment (NIPS) has become a promising therapeutic approach. This consensus aims to provide practical recommendations for NIPS treatment for gastric cancer with peritoneal metastasis (GCPM). The GRADE standards were used to rank evidence, and the Delphi method was employed for expert voting. 30 experts from China, Japan, South Korea, and Singapore participated in the development of this consensus. 28 experts participated in the voting process, which produced 29 statements covering diagnostic approaches, patient selection criteria, treatment regimens, management of intraperitoneal port placement, and conversion surgery considerations, and post-surgical treatment strategies in NIPS therapy. Based on current evidence and expert experience, these statements aim to improve the clinical outcomes of NIPS therapy for GCPM patients.

9 January 2020 in BMC Surgery
Verified
Journal Article
Open access
PDF file
BIRENDRA KUMAR SAHBIRENDRA KUMAR SAH
BIRENDRA KUMAR SAH
JLJ. Li
J. Li
CYChao Yan
Chao Yan
CLChen Li
Chen Li
MYM. Yan
M. Yan
ZZZhenggang Zhu
Zhenggang Zhu
Background: An appropriate method of anastomosis is crucial for gastric cancer patients who require gastrojejunal anastomosis. Surgeons have proposed different types of modified gastrojejunostomies in the last two decades. We focused on two types of standard anastomosis, i.e., Uncut Roux-Y and Roux-Y gastrojejunostomies, and compared the differences in immediate postoperative complications between the two types. Methods: This is a retrospective study on 236 gastric cancer patients who underwent curative distal gastrectomy with gastrojejunal Roux-Y or Uncut Roux-Y anastomosis for six consecutive years. Immediate postoperative complications were compared between the two groups. The authors discussed the causes of the significant complications and their management. Results: There was no difference in demographics between the two groups (92 Roux-y Versus 144 Uncut Roux-y). The overall complication rate was 20.8% with 1.4% anastomotic leakage in the Uncut Roux-Y group versus 33.7% with 7.6% anastomotic failures in the Roux-Y group (p < 0.05). More abdominal infections occurred in the Roux-Y anastomosis group compared with the Uncut Roux-Y anastomosis group (p < 0.05). Duration of postoperative stay was significantly longer in patients with Roux-y anastomosis group (p < 0.05). Conclusions: Considering the surgical simplicity and postoperative complications, the Uncut Roux-Y is a better choice for anastomosis in patients with gastric cancer undergoing gastrojejunostomy. A well-designed large cohort in a multi-centre randomized controlled trial is necessary to support these findings and compare other aspects.

26 July 2025 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
BSBowen Shi
Bowen Shi
SLSheng Lu
Sheng Lu
LZLuke Zhang
Luke Zhang
XWXinran Wang
Xinran Wang
YCYu Chen
Yu Chen
CYChao Yan
Chao Yan